TY - JOUR
T1 - Testosterone treatment combined with exercise to improve muscle strength, physical function and quality of life in men affected by inclusion body myositis
T2 - A randomised, double-blind, placebo-controlled, crossover trial
AU - Connor, Sophia G.
AU - Fairchild, Timothy J.
AU - Learmonth, Yvonne C.
AU - Beer, Kelly
AU - Cooper, Ian
AU - Boardman, Glenn
AU - Teo, Shaun Y.M.
AU - Shatahmasseb, Behnaz
AU - Zhang, Rui
AU - Hiscock, Krystyne
AU - Coudert, Jerome D.
AU - Yeap, Bu B.
AU - Needham, Merrilee
N1 - Funding Information:
Active medication and placebo were provided without cost by Lawley Pharmaceuticals, Western Australia (https://www.lawleypharm.com. au/). No other sources of funding (financial, material support or grants) were provided for this study. The authors received no specific funding for this work. Lawley Pharmaceuticals had no role in the study design, data collection and analysis, preparation of the manuscript or decision to publish.
Publisher Copyright:
© 2023 Connor et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2023/4
Y1 - 2023/4
N2 - Introduction Inclusion body myositis (IBM) is the most commonly acquired skeletal muscle disease of older adults involving both autoimmune attack and muscle degeneration. As exercise training can improve outcomes in IBM, this study assessed whether a combination of testosterone supplementation and exercise training would improve muscle strength, physical function and quality of life in men affected by IBM, more than exercise alone. Methods This pilot study was a single site randomised, double-blind, placebo-controlled, crossover study. Testosterone (exercise and testosterone cream) and placebo (exercise and placebo cream) were each delivered for 12 weeks, with a two-week wash-out between the two periods. The primary outcome measure was improvement in quadriceps isokinetic muscle strength. Secondary outcomes included assessment of isokinetic peak flexion force, walk capacity and patient reported outcomes, and other tests, comparing results between the placebo and testosterone arms. A 12-month Open Label Extension (OLE) was offered using the same outcome measures collected at 6 and 12-months. Results 14 men completed the trial. There were no significant improvements in quadriceps extension strength or lean body mass, nor any of the secondary outcomes. Improvement in the RAND Short Form 36 patient reported outcome questionnaire ‘emotional wellbeing’ sub-category was reported during the testosterone arm compared to the placebo arm (mean difference [95% CI]: 6.0 points, [95% CI 1.7,10.3]). The OLE demonstrated relative disease stability over the 12-month period but with a higher number of testosterone-related adverse events. Conclusions Adding testosterone supplementation to exercise training did not significantly improve muscle strength or physical function over a 12-week intervention period, compared to exercise alone. However, the combination improved emotional well-being over this period, and relative stabilisation of disease was found during the 12-month OLE. A longer duration trial involving a larger group of participants is warranted.
AB - Introduction Inclusion body myositis (IBM) is the most commonly acquired skeletal muscle disease of older adults involving both autoimmune attack and muscle degeneration. As exercise training can improve outcomes in IBM, this study assessed whether a combination of testosterone supplementation and exercise training would improve muscle strength, physical function and quality of life in men affected by IBM, more than exercise alone. Methods This pilot study was a single site randomised, double-blind, placebo-controlled, crossover study. Testosterone (exercise and testosterone cream) and placebo (exercise and placebo cream) were each delivered for 12 weeks, with a two-week wash-out between the two periods. The primary outcome measure was improvement in quadriceps isokinetic muscle strength. Secondary outcomes included assessment of isokinetic peak flexion force, walk capacity and patient reported outcomes, and other tests, comparing results between the placebo and testosterone arms. A 12-month Open Label Extension (OLE) was offered using the same outcome measures collected at 6 and 12-months. Results 14 men completed the trial. There were no significant improvements in quadriceps extension strength or lean body mass, nor any of the secondary outcomes. Improvement in the RAND Short Form 36 patient reported outcome questionnaire ‘emotional wellbeing’ sub-category was reported during the testosterone arm compared to the placebo arm (mean difference [95% CI]: 6.0 points, [95% CI 1.7,10.3]). The OLE demonstrated relative disease stability over the 12-month period but with a higher number of testosterone-related adverse events. Conclusions Adding testosterone supplementation to exercise training did not significantly improve muscle strength or physical function over a 12-week intervention period, compared to exercise alone. However, the combination improved emotional well-being over this period, and relative stabilisation of disease was found during the 12-month OLE. A longer duration trial involving a larger group of participants is warranted.
UR - http://www.scopus.com/inward/record.url?scp=85152244682&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0283394
DO - 10.1371/journal.pone.0283394
M3 - Article
C2 - 37040372
AN - SCOPUS:85152244682
SN - 1932-6203
VL - 18
JO - PLoS One
JF - PLoS One
IS - 4 April
M1 - e0283394
ER -